Press Releases 2018
Tessa Therapeutics announced that Dr. George W. Sledge, Jr., M.D., Professor and Chief of Medical Oncology at Stanford University Medical Center, will join Tessa’s Board of Directors as an independent director, effective 2 January 2019.
Tessa Therapeutics, a clinical stage biopharmaceutical company focusing on cellular immunotherapy treatments for cancer, today announced the appointment of Ivan D. Horak as President of Research and Development. In his new position, Dr. Horak will be responsible for all aspects of Tessa’s research and development, regulatory and clinical development activities.
St. Jude Children’s Research Hospital (St. Jude), the U.S. hospital leading the way the world understands, treats and cures childhood cancer and other life-threatening diseases, together with Tessa Therapeutics (Tessa), a clinical stage biopharmaceutical company, today announced the establishment of a strategic collaboration focusing on the development of novel cellular immunotherapies that could lead to new treatment options for children with brain cancer.
Tessa Therapeutics is delighted to announce that Göran Ando, the former Chairman of Novo Nordisk A/S, has joined the Board as an Independent Director. The company also announces that, due to additional demand in its latest funding round, it has raised a further USD 50m, bringing the total raised in this round to USD 130 million.
With the Stanford Cancer Institute joining as a clinical trial partner, Tessa’s Phase III trial for nose cancer (nasopharyngeal cancer) is now widely accessible across multiple locations in the U.S. The therapy is based on Tessa’s Virus-Specific T cell platform which is showing compelling results in the treatment of solid tumors.